Last Updated: May 11, 2026

Litigation Details for Taizhou Luqiao Shengqiang Housewares Factory v. Dbest Products Inc. (C.D. Cal. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Taizhou Luqiao Shengqiang Housewares Factory v. Dbest Products Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Taizhou Luqiao Shengqiang Housewares Factory v. Dbest Products Inc., 2:24-cv-10842

Last updated: February 24, 2026

What are the case details?

The case involves Taizhou Luqiao Shengqiang Housewares Factory asserting claims against Dbest Products Inc. in the U.S. District Court for the District of New Jersey under docket number 2:24-cv-10842. The dispute centers on alleged patent infringement related to houseware products, specifically focusing on design or utility patents held by Shengqiang.

Case timeline and procedural posture

  • Filing date: August 2024
  • Jurisdiction: U.S. District Court for the District of New Jersey
  • Parties:
    • Plaintiff: Taizhou Luqiao Shengqiang Housewares Factory (a Chinese manufacturer specializing in houseware products)
    • Defendant: Dbest Products Inc. (a U.S.-based distributor/importer of houseware products)
  • Claims: Patent infringement, likely involving design or utility patents owned by Shengqiang
  • Defendant’s response: Not yet filed; current stage involves complaint and summons issuance

What patents or intellectual property is involved?

Specific patent numbers are not included in the public docket summary. Typically, patent infringement suits in this sector involve:

  • Design patents: Covering ornamental aspects of houseware, such as handles or shapes
  • Utility patents: Covering functional features like lock mechanisms or stacking features

The infringement allegations refer to products having "substantially similar" ornamental or functional features, with patent claims asserting violations of unique design elements or mechanisms.

What legal claims does Shengqiang make?

  • Patent infringement: Dbest Products' houseware products infringe on Shengqiang’s patents
  • Unfair competition: The suit alleges Dbest’s conduct damages Shengqiang’s market share, citing false advertising or misrepresentation of non-infringement
  • Possible trade dress violation: If Shengqiang claims rights to the visual appearance or packaging style, they may extend the litigation scope

What defenses might Dbest raise?

  • Non-infringement: Argue that Dbest’s products do not violate patent claims
  • Patent invalidity: Assert patents are invalid due to prior art or obviousness
  • Patent scope: Challenge the validity or scope of the asserted claims
  • Willful infringement defense: May be raised if infringement is found, to reduce damages

What are potential remedies?

  • Injunction: Prevent Dbest from selling infringing products
  • Monetary damages: Compensation for past infringement, including royalties and possibly treble damages if willfulness is proven
  • Destruction or recall: Removal of infringing stock from the market

Market implications

Patent litigation in houseware often influences supply chains and distribution channels. A successful patent assertion by Shengqiang could result in:

  • Market exclusivity for certain product designs or features
  • Licensing opportunities if Dbest seeks to avoid infringement
  • Possible settlement negotiations, including licensing or monetary payments

Litigation trends and considerations

  • Cross-border IP issues: Since Shengqiang is Chinese and the defendant is American, enforcement involves international IP considerations
  • Patent validity challenges: Dbest may initiate IPR proceedings at the U.S. Patent and Trademark Office (USPTO) if the patents are issued
  • Rapid resolution potential: Patent cases typically proceed within 1-2 years, but complexities and appeals can extend timelines

Key takeaways

  • The case hinges on patent scope, validity, and infringement
  • Dbest is likely to contest claims through invalidity or non-infringement defenses
  • Outcomes could impact product distribution, licensing, and market competition
  • Enforcement involves not just U.S. patent law but international IP considerations
  • A settlement or licensing agreement remains a probable resolution pathway

FAQs

Q1: How common are patent infringement lawsuits in the houseware industry?
A: They are relatively frequent, especially where similar product designs and functionalities are involved, with companies seeking to protect unique innovations.

Q2: Can a Chinese manufacturer defend patents in the U.S.?
A: Yes, if the patents are valid and enforceable in the U.S., the manufacturer can defend or challenge claims through legal proceedings.

Q3: Will this case impact Dbest’s product availability?
A: Potentially, if an injunction is granted, Dbest may have to cease infringing product sales until resolution.

Q4: Are patent invalidity claims common in these disputes?
A: Yes, defendants often allege that patents are invalid due to prior art or obviousness to weaken patent protections.

Q5: What factors influence settlement likelihood in patent cases?
A: Patent scope, potential damages, market impact, and the strength of each party’s legal position affect settlement negotiations.


References

[1] U.S. District Court for the District of New Jersey. (2024). Case docket for Taizhou Luqiao Shengqiang Housewares Factory v. Dbest Products Inc., 2:24-cv-10842.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.